Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine
By Elana Gotkine HealthDay Reporter
MONDAY, June 30, 2025 -- For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability Assessment (MIDAS) scores, according to a study presented at the 11th Congress of the European Academy of Neurology, held from June 21 to 24 in Helsinki.
In a pilot prospective observational study, Simone Braca, M.D., from the University of Naples "Federico II" in Italy, and colleagues examined glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a potential promising approach to alleviating migraine in a pilot prospective observational study involving 26 patients with obesity and migraine who received subcutaneous liraglutide 1.2 mg daily for 12 weeks.
The researchers observed a decrease in mean monthly headache days from 20.04 ± 6.38 to 8.81 ± 6.01 after 12 weeks, and a reduction in MIDAS scores from 62.58 to 27.23. There was a decline seen in body mass index (BMI) from 34.01 to 33.65 kg/m2, but this was not statistically significant. BMI reduction was not found to influence headache frequency in analysis of covariance. Ten patients (38 percent) had mild gastrointestinal adverse events, mainly nausea and constipation, but these events did not prompt discontinuation.
"We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide, a key migraine-promoting peptide," Braca said in a statement. "That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
People With Obesity Value Respect and Being Listened to in Primary Care
THURSDAY, Sept. 4, 2025 -- Adults with obesity prefer a primary care visit characterized by respectful treatment and listening, according to a study published online in the...
14 Percent of U.S. Adults Initiate GLP-1 Receptor Agonist After Bariatric Surgery
WEDNESDAY, Sept. 3, 2025 -- Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published...
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 -- Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.